Piperidine derivatives as HDAC1/2 inhibitors
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
1. A compound of Formula III:
or a pharmaceutically acceptable salt thereof;
wherein,
X 1 is N;
X 2 is N;
R 1 is selected from the group consisting of H and C 1 -C 6 -alkyl;
R 2 is selected from the group consisting of H, C 1 -C 6 -alkyl, and C 6 -aryl;
R 3 is selected from the group consisting of H, C 1 -C 6 -alkyl, and C 6 -aryl;
or R 2 and R 3 together form a C 2 -C 6 -heterocyclyl;
R 4 is H; and
R 5 is C 1 -C 6 -alkyl;
or R 4 and R 5 together form a C 2 -C 6 -heterocyclyl, wherein heterocyclyl is optionally substituted by 1 or 2 of C 1 -C 6 -alkyl, halo, or hydroxy.
2. The compound of claim 1 , wherein R 2 is H.
3. The compound of claim 1 , wherein R 3 is H, methyl, or isopropyl.
4. The compound of claim 1 , wherein R 4 and R 5 together form a heterocyclyl selected from the group consisting of morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl, wherein the morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl are optionally substituted by 1 or 2 of C 1 -C 6 -alkyl, halo, or hydroxy.
5. The compound of claim 1 , wherein
R 1 is H;
R 2 is H;
R 3 is H or C 1 -C 4 -alkyl; and
R 4 and R 5 together form a heterocyclyl selected from the group consisting of morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl, wherein the morpholinyl, piperidinyl, piperazinyl, and pyrrolidinyl are optionally substituted by 1 or 2 of C 1 -C 6 -alkyl, halo, or hydroxy.
6. The compound of claim 1 , selected from:
or pharmaceutically acceptable salts thereof.
7. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.